Core Viewpoint - The company expects to achieve a net profit attributable to shareholders of no less than RMB 40 million in the first half of 2025, marking a turnaround from loss to profit primarily due to increased sales of newly launched hemorrhagic stroke treatment devices and effective cost control measures [1] Group 1 - The increase in revenue is driven by the sales growth of newly launched hemorrhagic stroke treatment devices and acute ischemic stroke treatment devices [1] - Effective cost control measures have led to a decrease in overall expense ratio, contributing to the company's profitability [1] - Changes in the research and development phase of projects have resulted in reduced R&D expenditures [1] - There has been an increase in fair value gains on financial assets measured at fair value through profit or loss [1]
心玮医疗-B(06609)发盈喜 预期上半年股东应占净利润不少于4000万元 同比扭亏为盈